Bladder cancer is the most common malignant tumor of the urinary system with high morbidity and no clear pathogenesis. The Hippo signaling pathway is an evolutionarily conserved pathway that regulates organ size and maintains tissue homeostasis. Yes-associated protein 1 (YAP1) is a key effector of this pathway and regulates downstream target genes by binding to transcriptional co-activators with PDZ binding sequences (TAZ). Several studies have demonstrated that YAP1 is overexpressed in bladder cancer and is involved in adverse outcomes such as bladder cancer occurrence, progression, resistance to cisplatin and the recurrence of tumours. The present review summarized the involvement of YAP1 in bladder cancer disease onset and progression, and the mechanism of YAP1 involvement in bladder cancer treatment. In addition, this study further explored the potential of YAP1 in the diagnosis and treatment of bladder cancer. This study aimed to explore the potential mechanism of YAP1 in the treatment of bladder cancer.
bladder canceryes-associated protein 1Hippo signaling pathwaytargeted therapydrug-resistantNational Natural Science Foundation of China81860524This study was supported by the National Natural Science Foundation of China (grant no. 81860524).Introduction
The Hippo signaling pathway is an evolutionarily conserved signal pathway that was first identified in Drosophila and plays an important role in the regulation of cell proliferation, apoptosis and tissue and organ growth (1,2). Yes-associated protein 1 (YAP1), a pivotal component of the Hippo signaling pathway, is encoded by the YAP1 gene located on human chromosome 11q22 and functions as an oncogenic protein (Fig. 1) (3). When the Hippo pathway is disrupted, mammalian STE20-like protein kinase 1/2 (Mst1/2) kinases become phosphorylated and activated, which in turn activates downstream large tumor suppressor kinase 1 and 2 ((LATS1/2) kinases. These activated LATS1/2 kinases phosphorylate YAP1, leading to its degradation in the cytoplasm (4). Conversely, dephosphorylated YAP1 translocates to the nucleus, binds to the TEA domain (TEAD) and promotes the transcription of downstream genes (for example, CTGF and Cyr61) (5,6).
YAP1/transcriptional co-activator with PDZ-binding motif (TAZ) play essential roles in regulating cell proliferation and are crucial for organ regeneration, development and stem cell self-renewal (7). They are influenced by various factors, including the microenvironment and extracellular signals. Additionally, YAP1 can activate survival pathways to inhibit apoptosis and interacts with multiple signaling networks (8), contributing to cancer development and progression (9). Elevated YAP1 expression is associated with malignant tumor recurrence, metastasis, reduced overall survival and chemotherapy resistance (10). In human cancers, YAP/TAZ target genes are associated with poor prognosis and increased treatment resistance (11). YAP1 is highly expressed in various cancers and linked to adverse outcomes, including bladder, colon, pancreatic, hepatocellular, gastric/esophageal, ovarian, brain, breast and lung cancers (12–17).
Bladder cancer is the most prevalent malignancy within the urinary system and is anticipated to rank as the ninth most common cancer in the United States by 2023 (18). Previous years have seen an increasing incidence of bladder cancer, with a trend toward younger patients (19). While the etiology remains incompletely understood, risk factors include smoking, aging and occupational exposures (20). Genetic mutations and altered RNA expression levels also contribute to bladder cancer risk. YAP1 is notably upregulated in bladder cancer and is associated with poor prognosis (21). Research indicates that single nucleotide polymorphisms (SNPs) in YAP1, a key molecule in the Hippo pathway, are linked to bladder cancer development (22). BCa is a cancer that frequently exhibits mutations. A study has indicated that in human bladder smooth muscle, Gene Ontology annotation analysis shows that differential genes are enriched in positive regulation of cellular processes, metabolism, protein binding and signal transduction processes. Kyoto Encyclopedia of Genes and Genomes enrichment analysis highlights genes in the MAPK and PI3K/Akt signaling pathways (23). Additionally, a next-generation sequencing study suggests that BCa is primarily associated with a high mutation burden in genes related to the cell cycle and chromatin regulation. Dysfunctional Hippo signaling may contribute to the development of bladder cancer, although it is not an independent driver (24). The present study reviews the carcinogenic mechanisms of YAP1 in bladder cancer and evaluates its potential as a therapeutic target.
Regulation of YAP1 activity in bladder cancer
YAP1 activity is controlled by its gene expression levels. Knockdown of this gene in bladder cancer cell lines significantly reduces YAP1 protein activity (21). Furthermore, the primary method of regulating YAP1 activity involves modulation of its phosphorylation status. When phosphorylated, YAP1 is retained in the cytoplasm and thus is unable to translocate to the nucleus to perform its transcriptional activation functions. 4-hydroxynonenal induces phosphorylation of YAP1 at serine residues 127 and 387, leading to reduced YAP1 expression and consequently decreases bladder cancer cell proliferation (25). Ubiquitination is regulated by deubiquitinases (DUBs), which are specialized Ub proteases that process Ub chains in various ways to regulate ubiquitination (26). MINDY1, a DUB specific to YAP1, removes the K48-linked ubiquitin chain from YAP1, thereby preventing its proteasomal degradation. This action enhances the stability and abundance of the YAP1 protein, consequently boosting its transcriptional activation capability and facilitating the progression of bladder cancer (Fig. 2) (27).
YAP1 participates in the progression of bladder cancer
Tumor cell proliferation and migration is a dynamic and intricate process that contributes to the advancement of numerous diseases. Abnormal cell proliferation often leads to tumor formation. Once tumor cells acquire the capability to migrate and detach from the primary site, they can significantly accelerate tumor dissemination and metastasis. Phosphorylated YAP1 not only directly influences tumor proliferation but also collaborates with various molecules to promote both tumor proliferation and migration. For instance, The drosophile Mask (multiple ankyrin repeats single KH domain) whose mammalian homologues MASK1 (also known as ANKHD1) and MASK2 (also known as GTAR or ANKRD17) are a novel cofactor of YAP1. In bladder cancer cell lines overexpressing YAP1, MASK2interacts with YAP1 to modulate its downstream target genes, consequently promoting the proliferation and migration of bladder cancer cells (28).
The MAPK pathway, ubiquitously present in organisms, potentially facilitates the onset and progression of cancer when its signaling becomes dysregulated (29). YAP1 serves as both an upstream regulator and an activator of the MAPK pathway. Its stimulation of the MAPK/ERK pathway synergistically promotes the proliferation and invasion of bladder cancer cells (30). Research demonstrates that YAP1 modulates the transcription of both long non-coding RNA (lncRNA) and mRNA (31). Specifically, lncRNA H19, a downstream target of YAP1, is upregulated by YAP1, influencing the proliferation and migration of bladder cancer cells (32). Furthermore, in bladder cancer, lncRNA H19 interacts with microRNA (miRNA/miR)-29b-3p, impacting epithelial-mesenchymal transition (EMT) and thereby facilitating cancer metastasis (33).
Furthermore, YAP1 can collaborate synergistically with miRNA to facilitate the progression of bladder cancer. MiRNAs, serving as critical regulatory factors in tumor development, are intricately linked to tumor formation, metastasis, cellular apoptosis and chemoresistance when expressed abnormally (34). A study by Luo (35) identified a cross-network interaction between the Hippo and TGF-β signaling pathways, where the YAP1-Smad3 complex plays a pivotal role. MiR-497 and miR-195 disrupt the formation of the YAP1/SMAD3 complex, thereby interfering with the interactions between the Hippo/YAP1 and TGF-β/Smad pathways. This disruption diminishes their influence on the shared target gene, connective tissue growth factor (CTGF), ultimately reducing bladder cancer cell proliferation (36). Furthermore, the overexpression of hypermethylated in cancer 1 suppresses CTGF activity, limits interactions between YAP1 and the TEAD, and inhibits proliferation, migration and invasion of bladder cancer cells (37). Additionally, miR-599 curtails proliferation and invasion, while enhancing apoptosis in bladder urothelial carcinoma cells by modulating YAP1 expression (38).
Exosomes, a type of extracellular vesicle, are secreted by virtually all cell types. These vesicles support a wide array of cellular functions, encompassing intercellular communication, cell differentiation and proliferation, angiogenesis, stress responses and immune signaling (39,40). Research demonstrates a distinct relationship between exosomes and YAP1, where exosomal miR-217 from normal human bladder stromal cells is significantly elevated in bladder cancer cell lines, and by modulating YAP1 and its downstream targets, cysteine-rich angiogenic inducer 61 (CYR61), CTGF and ankyrin repeat domain-containing protein 1 miR-217 mimics or inhibitors can notably influence the proliferation, migration, and apoptosis of bladder cancer cells (41).
EMT is a critical process in tumor metastasis and a hallmark of malignant tumors. Additionally, EMT is integral to embryogenesis and wound healing (42,43). In a study, high-glucose culture media induces YAP1 and TAZ expression in bladder cancer cells, resulting in the upregulation of wave protein, N-cadherin, and fibronectin, alongside the downregulation of E-cadherin to promote EMT, while also regulating glucose metabolism through glucose transporter type 1 activity, thereby highlighting the Hippo signaling pathway as a crucial factor in the dysregulation of glucose metabolism in bladder cancer (Table I) (44).
Stem cells (SCs) are multipotent cells with the capacity for self-renewal. Provided specific conditions, these cells can differentiate into a variety of functional cell types (45,46). Cancer SCs (CSCs) are characterized by their capacity for self-renewal and differentiation. These cells significantly contribute to tumor progression, treatment resistance and disease recurrence by continuously proliferating, invading normal tissues and exhibiting resistance to conventional cancer therapies (47,48).
YAP1 is pivotal in regulating several key processes in CSCs, including self-renewal, multilineage differentiation, tumorigenesis, treatment resistance and metastatic invasion (49,50). In embryonic, neural and hematopoietic stem cells, elevated expression of the YAP1-TEAD2 complex sustains stem cell potency and serves as an indicator of stemness (51). YAP1, a regulator of stem cell functions, is notably upregulated in bladder cancer stem cells. The overexpression of YAP significantly enhances the self-renewal ability of these cells (52). YAP1 collaborates with the pro-inflammatory cyclooxygenase 2 (COX2)/prostaglandin E2 (PGE2) signaling pathway to enhance the proliferation of bladder urothelial carcinoma stem-like cells and influence tumor chemoresistance. As the COX2/PGE2 pathway induces methylation of the let-7 promoter, this results in reduced let-7 expression and subsequent upregulation of SRY-box transcription factor 2 (SOX2), which is further amplified by YAP1′s binding to the SOX2 enhancer, thereby increasing SOX2 expression (53). The interaction between the COX2 and YAP1 pathways may significantly influence the recurrence of bladder cancer.
Furthermore, the miR-146a rs2910164 SNP genotype C>G significantly affects the prognosis of bladder cancer patients by modulating key targets within the Hippo and COX2 signaling pathways, leading to the suppression of YAP1 and COX2 at both mRNA and protein levels, which results in the downregulation of YAP1 and aldehyde dehydrogenase 1 family, member A1, along with reduced expression of COX2 and SOX2, all of which are closely associated with bladder cancer recurrence (54). Simultaneously, a study has demonstrated that YAP1 is involved in its own recurrence process. During the postoperative wound healing phase in bladder cancer, it has been observed that the extracellular matrix regulates the transport of YAP1 to the nucleus through integrin-FAK-YAP1 signaling. This regulation contributes to the progression and recurrence of bladder cancer (55).
This implies that YAP1 overexpression not only affects bladder cancer progression through interactions with multiple signaling pathways but also contributes to this progression by regulating the stemness of tumor stem cells. Consequently, targeting YAP1 and its associated regulatory network could provide novel therapeutic approaches for bladder cancer.
Therapeutic potential of YAP1-targeting in bladder cancer
Bladder urothelial carcinoma is classified into two main categories based on clinical staging, each with different clinical outcomes and treatment options: Muscle invasive bladder cancer (MIBC) and non-MIBC (NMIBC). Treatment decisions are primarily based on clinical factors. Besides surgery, common treatments currently include cisplatin chemotherapy, immunotherapy and targeted therapy. Despite these options, the treatment outlook for bladder cancer remains unsatisfactory, with a high risk of recurrence. Although the targeting of cancer treatment signaling pathways has increased over the past few decades, bladder cancer requires the exploration of potentially more effective treatments (Table II).
YAP1 and chemotherapy resistance in bladder cancer
Chemotherapy remains a cornerstone of treatment for malignant tumors, with cisplatin used across a spectrum of cancers, including bladder cancer (56–58). Yet, the emergence of cisplatin resistance has notably diminished its therapeutic effectiveness (59,60). Moreover, the redox state, crucial in the adaptation of cancer cells to therapeutic stresses, significantly influences chemoresistance (61). Research demonstrates that YAP1 activation plays a pivotal role in conferring resistance across targeted therapy, chemotherapy, radiotherapy and possibly immunotherapy, thus establishing it as a critical mediator of chemoresistance in diverse cancers (62,63).
The YAP1/TEAD complex is known to regulate Forkhead box protein M1(FOXM1) expression, which in turn affects nuclear factor erythroid 2-related factor 2 (Nrf2) expression (64). Both Nrf2 and YAP1 contribute to the antioxidative capacity of bladder cancer cells, with a positive association observed between the expression levels of YAP1 and Nrf2. Targeted inhibition of YAP1 and Nrf2, aimed at decreasing cell viability, inducing apoptosis and curbing cancer cell migration, has been shown to substantially enhance the sensitivity of these cells to cisplatin (66). The transcription factor Nrf2 is a pivotal regulator of antioxidant defenses and cellular protection mechanisms, playing a significant role in mediating cisplatin resistance in bladder cancer (66). Emerging research based on the interaction between YAP1 and Nrf2 indicates that Ailanthone (Aila) can potentially serve as an effective therapeutic for cisplatin-resistant bladder cancer. Notably, Aila consistently suppresses Nrf2 expression while concurrently inhibiting YAP1 and c-Myc, thereby sustaining a robust anti-proliferative effect on cisplatin-resistant cells (67). Additionally, Aila markedly decreases the expression of the Nrf2 target glutathione S-transferase A4 and the YAP1/TEAD target survivin. In cisplatin-resistant bladder cancer cells, levels of intracellular oxidative stress are notably lower compared with those in cisplatin-sensitive cells. The post-translational downregulation of Nrf2 and YAP1 proteins can effectively reduce cancer cell proliferation and migration, while simultaneously increasing oxidative stress in chemotherapy-resistant bladder cancer cell lines (68). Decitabine, a DNA methyltransferase inhibitor, demonstrates cytotoxic effects at high doses by directly inducing cell death. At lower doses, it reactivates silenced genes via demethylation of promoter regions and is extensively employed in the treatment of diseases such as leukemia (69).
In bladder cancer cells, decitabine reactivates the Hippo signaling pathway through the restoration of Ras association domain-containing protein 1, concurrently inhibiting YAP1 expression and reducing the expression of its oncogenic downstream targets, including CTGF and CYR61. Furthermore, decitabine enhances the cytotoxic effects of cisplatin and doxorubicin in these cells (70). YAP1 expression and activation are inversely correlated with cisplatin sensitivity both in vitro and in vivo. The YAP1 inhibitor verteporfin has been demonstrated to inhibit tumor cell proliferation and enhance cisplatin sensitivity in bladder cancer cells. Inhibition of YAP1 expression increases DNA damage and promotes apoptosis accumulation, thereby sensitizing urothelial carcinoma cells to radiochemotherapy. Notably, nuclear YAP1 expression is linked to adverse outcomes in patients with urothelial carcinoma undergoing perioperative chemotherapy (71). The YAP1/TEAD1/PDGF-BB/PDGFR autocrine loop plays a pivotal role in sustaining the characteristics of tumor stem-like cells. Inhibition of YAP1 has been shown to significantly reduce cisplatin resistance in OV6-positive bladder cancer stem-like cells, a finding corroborated by animal model studies.
YAP1 and bladder cancer immunotherapy
Immunotherapy is a treatment method aimed at enhancing the body's immune system or modifying the ongoing cancer defense mechanisms to combat cancer (72,73). In recent years, immunotherapy has gained prominence in cancer treatment and has undergone rapid development (74). In bladder cancer, Bacillus Calmette-Guérin (BCG) remains the preferred immunotherapy for NMIBC, effectively stimulating immune responses and modulating the immune system to produce antitumor effects, thereby significantly reducing recurrence rates and prolonging the interval between recurrences (75,76). Nevertheless, ~1/3 of patients with NMIBC do not respond to BCG therapy. A previous study indicates that combining programmed cell death protein 1 (PD-1) inhibitors with BCG treatment is a safe and potentially effective strategy for these non-responders (77). Additionally, immune checkpoint inhibitors (ICIs) such as PD-1 and programmed death-ligand 1 (PD-L1) antibodies are approved for bladder cancer treatment. These ICIs can directly interact with the urothelium or malignant cells on the bladder mucosa, initiating active immune responses (78). Baek et al (79) revealed three molecular subtypes of advanced urothelial carcinoma through gene expression analysis, which have potential clinical application value in predicting responses to immune checkpoint inhibitor therapy and patient prognosis. Among these, the inactivation of the YAP/TAZ pathway in the third subtype is associated with the activation of cell cycle and DNA damage response pathways. This suggests that in patients with the third subtype, the inactivation of the YAP/TAZ pathway might be related to a good response to ICI therapy and improved prognosis (79). Further research by Baek et al (80) categorized YAP1 activation into three distinct subtypes based on differential gene expression and integrated this classification with immunotherapy prognostic analysis for patients. This analysis suggests that NMIBC subgroups with YAP1 activation might derive significant benefit from ICI treatments. Additionally, the activation status of YAP1 in NMIBC is not only associated with the biological behavior of the disease but also has the potential to serve as a crucial biomarker for predicting treatment response and patient prognosis (80).
YAP1 and targeted therapy for bladder cancer
Based on platinum-based chemotherapy, which serves as the first-line treatment for patients with NMIBC, survival rates are improved but still remain relatively low (81). Advances in targeted therapies, which have transformed treatment paradigms in various cancers, are only beginning to make inroads into bladder cancer (82,83). Approved treatments such as PD-1/PD-L1 inhibitors, the fibroblast growth factor receptor inhibitor Erdafitinib, and Enfortumab vedotin (an antibody-drug conjugate directed at Nectin-4 that comprises a fully human, monoclonal antibody and the microtubule-disrupting agent, monomethyl auristatin E) have shown promise (84). Notably, Enfortumab vedotin has achieved a remission rate of ~8% in patients with locally advanced or metastatic bladder cancer previously treated with platinum-based and anti-PD-1/PD-L1 therapies (85). Furthermore, the YAP1-specific inhibitor, Verteporfin (VP), demonstrates potential as a targeted therapeutic by inhibiting YAP1-induced gene expression within the Hippo pathway and reducing the proliferation and invasion of bladder cancer cells in a dose-dependent manner (86). Dual treatment involving Crizotinib and VP in canine bladder cancer organoids significantly reduce cell vitality by inducing apoptosis, underscoring the potential of combining Crizotinib with VP (87). An additional study has explored the synergistic effects of Verteporfin and the RhoA inhibitor Simvastatin, which counteract the proliferative and metastatic activities induced by PLAGL2. Protein kinase membrane-associated tyrosine/threonine 1, another direct target of YAP1/TEAD1, is implicated in activating the YAP1/TAZ pathway, further highlighting the complex regulatory mechanisms in bladder cancer pathogenesis (88).
Limitations and prospects
YAP1, recognized as an oncogene (89), plays critical roles in cell proliferation, migration, epithelial-mesenchymal transition, stemness and chemotherapy resistance across various malignancies, including bladder cancer. However, research on YAP1 in bladder cancer mainly focuses on bladder transitional cell carcinoma, and there is a lack of exploration regarding the expression and mechanisms of YAP1 in other subtypes of bladder cancer (such as bladder squamous cell carcinoma, bladder adenocarcinoma and bladder sarcoma). Despite its established significance in the molecular mechanisms underlying bladder cancer, in vivo experimental validation remains limited, and the regulatory mechanisms of the upstream factors of YAP1 are poorly understood. Enhanced exploration of the HIPPO signaling pathway's interactions in bladder cancer could revolutionize diagnostic and therapeutic approaches. Currently, post-translational modifications of YAP1 are extensively studied in various human solid tumors (90–92). Ubiquitination modification of YAP1 has been confirmed to be of significant importance for tumor progression in multiple tumors (14,93).
Additionally, glycosylation modification of YAP1 can increase its stability, promoting the malignant development of chronic kidney disease (94). Previous research findings suggest that metabolic pathways play a role in regulating YAP/TAZ activity. Glycolysis, energy stress and mevalonate biosynthesis have been identified as regulators of YAP/TAZ activity (95). Currently, glucose metabolism is a hotspot in tumor research. At present, metabolic diagnostics can improve accuracy and affordability (96). YAP1 is also involved in the tumor glycolysis process and is considered a glucose metabolism regulator. YAP1 mediates cardiac hypertrophy induced by pressure overload through aerobic glycolysis (97). In thyroid tumors and liver tumors, high glucose levels regulate YAP1 activity and promote tumor progression (98,99). In bladder tumors, research has shown that extracellular glucose levels regulate YAP1 and promote the progression of bladder cancer EMT (44). In bladder cancer, YAP1 is not only related to glucose metabolism but also acts as an oncogene and glycoprotein, making it a promising tumor marker for bladder cancer. Currently, research combines composite materials with metabolic analysis to screen for potential biomarkers (100). YAP1 is expected to become a biomarker in bladder cancer; however, extensive clinical data is still needed to clarify the sensitivity and specificity of YAP1.
YAP1, known as a cancer stem cell marker, contributes to the progression of bladder cancer. However, while a previous study has examined YAP1′s interactions with other molecular pathways affecting cancer stem cell dynamics, the exact mechanisms of YAP1′s involvement in these processes remain poorly defined (49). Research indicates that YAP1/TAZ may be a new decisive factor in ferroptosis (101). Activation of ferroptosis can specifically target and kill certain cancer cells, leading to improved survival rates. Ferroptosis is currently a major focus in tumor research. Meanwhile, a single study suggests that nanomaterials and copper ions could offer new approaches for tumor treatment (102). However, there are currently no reports on the interaction between YAP1 and ferroptosis in bladder cancer.
Although YAP1-targeted inhibitors have demonstrated efficacy in various cancers, research specifically addressing these inhibitors in bladder cancer is sparse, and their molecular mechanisms of action are not well understood. Additionally, YAP1 expression is closely linked to the occurrence, size and stage of bladder cancer, highlighting its potential as a biomarker. Despite the high recurrence rate of bladder cancer, research into the fundamental mechanisms driving this recurrence is inadequate. Notably, the expression of YAP1 is associated with recurrence rates, but detailed investigations into how YAP1 contributes to bladder cancer recurrence are still required.
Conclusion
In summary, there is a critical need for comprehensive studies in bladder cancer focusing on several key areas: i) The interactions of the Hippo signaling pathway with YAP1, particularly its post-translational modifications and their impact on tumor progression; ii) the dynamics between YAP1 and glucose metabolism; iii) the role of YAP1 in bladder cancer stem cell behavior; iv) the effectiveness of YAP1-targeted inhibitors in clinical treatment; and v) the specific mechanisms through which YAP1 contributes to bladder cancer recurrence. Given its significant influence on various cancer-related processes, YAP1 holds great promise as a novel biomarker and therapeutic target for bladder cancer.
Acknowledgements
Not applicable.
Availability of data and materials
Not applicable.
Authors' contributions
TH contributed to the creation of figures, drafted the manuscript and conducted research. LF contributed to table creation and drafted the manuscript. JT contributed to revision of the manuscript. SC contributed to drafting the original manuscript. GD contributed to drafting manuscript. ZN contributed to the conceptual design, provided resources, oversaw the project and reviewed and edited the manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesMisraJRIrvineKDThe Hippo signaling network and its biological functionsAnnu Rev Genet526587201810.1146/annurev-genet-120417-03162130183404MaSMengZChenRGuanKLThe Hippo pathway: Biology and pathophysiologyAnnu Rev Biochem88577604201910.1146/annurev-biochem-013118-11182930566373LorenzettoEBrencaMBoeriMVerriCPiccininEGaspariniPFacchinettiFRossiSSalvatoreGMassiminoMYAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypesOncotarget526082621201410.18632/oncotarget.184424810989WuZGuanKLHippo signaling in embryogenesis and developmentTrends Biochem Sci465163202110.1016/j.tibs.2020.08.00832928629PocaterraARomaniPDupontSYAP/TAZ functions and their regulation at a glanceJ Cell Sci133jcs230425202010.1242/jcs.23042531996398ZanconatoFCordenonsiMPiccoloSYAP/TAZ at the roots of cancerCancer Cell29783803201610.1016/j.ccell.2016.05.00527300434ZhongZJiaoZYuFXThe Hippo signaling pathway in development and regenerationCell Rep43113926202410.1016/j.celrep.2024.11392638457338MorcianoGVezzaniBMissiroliSBoncompagniCPintonPGiorgiCAn updated understanding of the role of YAP in driving oncogenic responsesCancers (Basel)133100202110.3390/cancers1312310034205830AbylkassovRXieYRole of Yes-associated protein in cancer: An updateOncol Lett1222772282201610.3892/ol.2016.495527698789GalskyMDStenslandKDMoshierESfakianosJPMcBrideRBTsaoCKCaseyMBoffettaPOhWKMazumdarMWisniveskyJPEffectiveness of adjuvant chemotherapy for locally advanced bladder cancerJ Clin Oncol34825832201610.1200/JCO.2015.64.107626786930LuoJDengLZouHGuoYTongTHuangMLingGLiPNew insights into the ambivalent role of YAP/TAZ in human cancersJ Exp Clin Cancer Res42130202310.1186/s13046-023-02704-237211598FuMHuYLanTGuanKLLuoTLuoMThe Hippo signalling pathway and its implications in human health and diseasesSignal Transduct Target Ther7376202210.1038/s41392-022-01191-936347846ZhaoXFuJHuBChenLWangJFangJGeCLinHPanKFuLSerine metabolism regulates YAP activity through USP7 in colon cancerFront Cell Dev Biol9639111202110.3389/fcell.2021.63911134055773ZhuHYanFYuanTQianMZhouTDaiXCaoJYingMDongXHeQYangBUSP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP/TAZCancer Res8022042216202010.1158/0008-5472.CAN-19-238832217697EiblGRozengurtEKRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loopsSemin Cancer Biol545062201910.1016/j.semcancer.2017.10.00729079305LeeJYChangJKDominguezAALeeHPNamSChangJVarmaSQiLSWestRBChaudhuriOYAP-independent mechanotransduction drives breast cancer progressionNat Commun101848201910.1038/s41467-019-09755-031015465DriskillJHPanDThe Hippo pathway in liver homeostasis and pathophysiologyAnnu Rev Pathol16299322202110.1146/annurev-pathol-030420-10505033234023SiegelRLMillerKDFuchsHEJemalACancer statistics, 2022CA Cancer J Clin72733202210.3322/caac.2170835020204AntoniSFerlayJSoerjomataramIZnaorAJemalABrayFBladder cancer incidence and mortality: A global overview and recent trendsEur Urol7196108201710.1016/j.eururo.2016.06.01027370177LenisATLecPMChamieKMshsMDBladder cancer: A reviewJAMA32419801991202010.1001/jama.2020.1759833201207LiuJYLiYHLinHXLiaoYJMaiSJLiuZWZhangZLJiangLJZhangJXKungHFOverexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladderBMC Cancer13349201310.1186/1471-2407-13-34923870412HuangZWangXMaLGuoZLiuHDuMChuHWangMWangZZhangZGenetic variations in Hippo pathway genes influence bladder cancer risk in a Chinese populationArch Toxicol94785794202010.1007/s00204-020-02663-z32123962DiXXiangLJianZYAP-mediated mechanotransduction in urinary bladder remodeling: Based on RNA-seq and CUT&TagFront Genet141106927202310.3389/fgene.2023.110692736741311TongTHuangMYanBLinBYuJTengQLiPPangJHippo signaling modulation and its biological implications in urological malignanciesMol Aspects Med98101280202410.1016/j.mam.2024.10128038870717CucciMACompagnoneADagaMGrattarolaMUllioCRoettoAPalmieriARosaACArgenzianoMCavalliRPost-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cellsFree Radic Biol Med141205219201910.1016/j.freeradbiomed.2019.06.00931207288ZhangQJiangJRegulation of hedgehog signal transduction by ubiquitination and deubiquitinationInt J Mol Sci2213338202110.3390/ijms22241333834948134LuoYZhouJTangJZhouFHeZLiuTLiuTMINDY1 promotes bladder cancer progression by stabilizing YAPCancer Cell Int21395202110.1186/s12935-021-02095-434315490DongLLinFWuWHuangWCaiZTranscriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cellJ Cancer721322138201610.7150/jca.1643827877230RovidaETusaITargeting MAPK in cancer 2.0Int J Mol Sci235702202210.3390/ijms2310570235628511QiuDZhuYCongZYAP triggers bladder cancer proliferation by affecting the MAPK pathwayCancer Manag Res121220512214202010.2147/CMAR.S27344233273857WangJWangHZhangYZhenNZhangLQiaoYWengWLiuXMaLXiaoWMutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancerCell Signal2610481059201410.1016/j.cellsig.2014.01.02224468535LiSYuZChenSSLiFLeiCYChenXXBaoJMLuoYLinGZPangSYTanWLThe YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNAUrol Oncol33427.e1e10201510.1016/j.urolonc.2015.06.00326163939LvMZhongZHuangMTianQJiangRChenJlncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNABiochim Biophys Acta Mol Cell Res186418871899201710.1016/j.bbamcr.2017.08.00128779971JafriIMiRNA a new insight in metabolic and human diseases: A reviewCell Mol Biol (Noisy-le-grand)69102110202310.14715/cmb/2023.69.8.1637715412LuoKSignaling cross talk between TGF-β/Smad and other signaling pathwaysCold Spring Harb Perspect Biol9a022137201710.1101/cshperspect.a02213727836834ZhuangCLiuYFuSYuanCLuoJHuangXYangWXieWZhuangCSilencing of lncRNA MIR497HG via CRISPR/Cas13d induces bladder cancer progression through promoting the crosstalk between Hippo/Yap and TGF-β/Smad signalingFront Mol Biosci7616768202010.3389/fmolb.2020.61676833363213ZhouXZhangPHanHLeiHZhangXHypermethylated in cancer 1 (HIC1) suppresses bladder cancer progression by targeting yes-associated protein (YAP) pathwayJ Cell Biochem12064716481201910.1002/jcb.2793830417565ZhangJDengXEffects of miR-599 targeting YAP1 on proliferation, invasion and apoptosis of bladder urothelial carcinoma cellsExp Mol Pathol118104599202110.1016/j.yexmp.2020.10459933359177HadeMDSuireCNSuoZMesenchymal stem cell-derived exosomes: Applications in regenerative medicineCells101959202110.3390/cells1008195934440728KalluriRLeBleuVSThe biology, function, and biomedical applications of exosomesScience367eaau6977202010.1126/science.aau697732029601HuangZMWangHJiZGBladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathwayInflamm Res70959969202110.1007/s00011-021-01494-734390377Schmitz-DrägerBJDrollerMLokeshwarVBLotanYHudsonMAvan RhijnBWMarbergerMJFradetYHemstreetGPMalmstromPUMolecular markers for bladder cancer screening, early diagnosis, and surveillance: The WHO/ICUD consensusUrol Int94124201510.1159/00036935725501325LamouilleSXuJDerynckRMolecular mechanisms of epithelial-mesenchymal transitionNat Rev Mol Cell Biol15178196201410.1038/nrm375824556840LiSZhuHChenHXiaJZhangFXuRLinQGlucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZJ Cell Mol Med241039110401202010.1111/jcmm.1565332678516ZakrzewskiWDobrzyńskiMSzymonowiczMRybakZStem cells: Past, present, and futureStem Cell Res Ther1068201910.1186/s13287-019-1165-530808416FuchsEBlauHMTissue stem cells: Architects of their nichesCell Stem Cell27532556202010.1016/j.stem.2020.09.01133007238HuangTSongXXuDTiekDGoenkaAWuBSastryNHuBChengSYStem cell programs in cancer initiation, progression, and therapy resistanceTheranostics1087218743202010.7150/thno.4164832754274NassarDBlanpainCCancer stem cells: Basic concepts and therapeutic implicationsAnnu Rev Pathol114776201610.1146/annurev-pathol-012615-04443827193450DriskillJHPanDControl of stem cell renewal and fate by YAP and TAZNat Rev Mol Cell Biol24895911202310.1038/s41580-023-00644-537626124LuoJLiPContext-dependent transcriptional regulations of YAP/TAZ in stem cell and differentiationStem Cell Res Ther1310202210.1186/s13287-021-02686-y35012640DamkhamNIssaragrisilSLorthongpanichCRole of YAP as a mechanosensing molecule in stem cells and stem cell-derived hematopoietic cellsInt J Mol Sci2314634202210.3390/ijms23231463436498961ZhaoAYDaiYJLianJFHuangYLinJGDaiYBXuTWYAP regulates ALDH1A1 expression and stem cell property of bladder cancer cellsOnco Targets Ther1166576663201810.2147/OTT.S17085830349299OokiADel Carmen Rodriguez PenaMMarchionniLDinalankaraWBegumAHahnNMVandenBusscheCJRasheedZAMaoSNettoGJYAP1 and COX2 coordinately regulate urothelial cancer stem-like cellsCancer Res78168181201810.1158/0008-5472.CAN-17-083629180467WangTYangYWangZZhangXLiDWeiJA SNP of miR-146a is involved in bladder cancer relapse by affecting the function of bladder cancer stem cells via the miR-146a signallingsJ Cell Mol Med2485458556202010.1111/jcmm.1548032596945GhasemiHMousavibaharSHHashemniaMKarimiJKhodadadiIMirzaeiFTavilaniHTissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resectionAnn N Y Acad Sci14734861202010.1111/nyas.1435832428277GwakHSYounSMKwonAHLeeSHKimJHRheeCHACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: Phase II studyJ Neurooncol75173180200510.1007/s11060-005-1858-816132508GentilinENew advancements in cisplatin-based treatmentsInt J Mol Sci245920202310.3390/ijms2406592036982994Gómez-RuizSMaksimović-IvanićDMijatovićSKaluđerovićGNOn the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapyBioinorg Chem Appl2012140284201210.1155/2012/14028422844263GalluzziLSenovillaLVitaleIMichelsJMartinsIKeppOCastedoMKroemerGMolecular mechanisms of cisplatin resistanceOncogene3118691883201210.1038/onc.2011.38421892204WenmaekersSViergeverBJKumarGKranenburgOBlackPCDaugaardMMeijerRPA potential role for HUWE1 in modulating cisplatin sensitivityCells101262202110.3390/cells1005126234065298RebucciMMichielsCMolecular aspects of cancer cell resistance to chemotherapyBiochem Pharmacol8512191226201310.1016/j.bcp.2013.02.01723435357NguyenCDKYiCYAP/TAZ Signaling and resistance to cancer therapyTrends Cancer5283296201910.1016/j.trecan.2019.02.01031174841KimMHKimJRole of YAP/TAZ transcriptional regulators in resistance toanti-cancer therapiesCell Mol Life Sci7414571474201710.1007/s00018-016-2412-x27826640FanQCaiQXuYFOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancerOncotarget62768827699201510.18632/oncotarget.428026299613CiamporceroEDagaMPizzimentiSRoettoADianzaniCCompagnoneAPalmieriAUllioCCangemiLPiliRBarreraGCrosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancerFree Radic Biol Med115447457201810.1016/j.freeradbiomed.2017.12.00529248722HaydenADouglasJSommerladMAndrewsLGouldKHussainSThomasGJPackhamGCrabbSJThe Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancerUrol Oncol32806814201410.1016/j.urolonc.2014.02.00624837013DagaMPizzimentiSDianzaniCCucciMACavalliRGrattarolaMFerraraBScariotVTrottaFBarreraGAilanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expressionPhytomedicine56156164201910.1016/j.phymed.2018.10.03430668336CucciMAGrattarolaMDianzaniCDamiaGRicciFRoettoATrottaFBarreraGPizzimentiSAilanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanismFree Radic Biol Med150125135202010.1016/j.freeradbiomed.2020.02.02132101771DhillonSDecitabine/cedazuridine: First approvalDrugs8013731378202010.1007/s40265-020-01347-332860582KhandelwalMAnandVAppunniSSethASinghPMathurSSharmaADecitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1AMol Cell Biochem446105114201810.1007/s11010-018-3278-z29368096CiamporceroEShenHRamakrishnanSYu KuSChintalaSShenLAdelaiyeRMilesKMUllioCPizzimentiSYAP activation protects urothelial cell carcinoma from treatment-induced DNA damageOncogene3515411553201610.1038/onc.2015.21926119935HongWXHaebeSLeeASWestphalenCBNortonJAJiangWLevyRIntratumoral immunotherapy for early-stage solid tumorsClin Cancer Res2630913099202010.1158/1078-0432.CCR-19-364232071116DemariaOGauthierLDebroasGVivierENatural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatmentsEur J Immunol5119341942202110.1002/eji.20204895334145579RuiRZhouLHeSCancer immunotherapies: Advances and bottlenecksFront Immunol141212476202310.3389/fimmu.2023.121247637691932HanJGuXLiYWuQMechanisms of BCG in the treatment of bladder cancer-current understanding and the prospectBiomed Pharmacother129110393202010.1016/j.biopha.2020.11039332559616DoninNMLenisATHoldenSDrakakiAPantuckABelldegrunAChamieKImmunotherapy for the treatment of urothelial carcinomaJ Urol1971422201710.1016/j.juro.2016.02.300527460757GillJPrasadVPembrolizumab for non-muscle-invasive bladder cancer-a costly therapy in search of evidenceJAMA Oncol7501502202110.1001/jamaoncol.2020.614233377964SongDPowlesTShiLZhangLIngersollMALuYJBladder cancer, a unique model to understand cancer immunity and develop immunotherapy approachesJ Pathol249151165201910.1002/path.530631102277BaekSWJangIHKimSKNamJKLeemSHChuISTranscriptional profiling of advanced urothelial cancer predicts prognosis and response to immunotherapyInt J Mol Sci211850202010.3390/ijms2105185032182655BaekSWMunJYJangIHYangGEJeongMSKimSKNamJKChuISLeemSHYAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancerEBioMedicine81104092202210.1016/j.ebiom.2022.10409235665684GrossmanHNataleRBTangenCMSpeightsVOVogelzangNJTrumpDLdeVere WhiteRWSarosdyMFWoodDPJrRaghavanDCrawfordEDNeoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerN Engl J Med349859866200310.1056/NEJMoa02214812944571JooWDVisintinIMorGTargeted cancer therapy-are the days of systemic chemotherapy numbered?Maturitas76308314201310.1016/j.maturitas.2013.09.00824128673Pérez-HerreroEFernández-MedardeAAdvanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapyEur J Pharm Biopharm935279201510.1016/j.ejpb.2015.03.01825813885RouprêtMSeisenTBirtleAJCapounOCompératEMDominguez-EscrigJLGürses AnderssonILiedbergFMariappanPHugh MostafidAEuropean association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 UpdateEur Urol844964202310.1016/j.eururo.2023.03.01336967359YuEYPetrylakDPO'DonnellPHLeeJLvan der HeijdenMSLoriotYSteinMNNecchiAKojimaTHarrisonMREnfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2 trialLancet Oncol22872882202110.1016/S1470-2045(21)00094-233991512DongLLinFWuWLiuYHuangWVerteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathwayInt J Med Sci15645652201810.7150/ijms.2346029725256ElbadawyMSatoYMoriTGotoYHayashiKYamanakaMAzakamiDUchideTFukushimaRYoshidaTAnti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanismCancer Biol Ther22357371202110.1080/15384047.2021.191900434034619ChenHYangWLiYJiZPLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signalingCell Death Dis14433202310.1038/s41419-023-05970-237454211SudolMYAP1 oncogene and its eight isoformsOncogene323922201310.1038/onc.2012.52023160371FangLTengHWangYLiaoGWengLLiYWangXJinJJiaoCChenLSET1A-mediated mono-methylation at K342 regulates YAP activation by blocking its nuclear export and promotes tumorigenesisCancer Cell34103118.e9201810.1016/j.ccell.2018.06.00230008322MaoBHuFChengJWangPXuMYuanFMengSWangYYuanZBiWSIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinomaOncogene3314681474201410.1038/onc.2013.8823542177YanFQianMHeQZhuHYangBThe posttranslational modifications of Hippo-YAP pathway in cancerBiochim Biophys Acta Gen Subj1864129397202010.1016/j.bbagen.2019.07.00631306710WuLOuZLiuPZhaoCTongSWangRLiYYuanJChenMFanBATXN3 promotes prostate cancer progression by stabilizing YAPCell Commun Signal21152202310.1186/s12964-023-01073-937349820XuTHShengZLiYQiuXTianBYaoLOGT knockdown counteracts high phosphate-induced vascular calcification in chronic kidney disease through autophagy activation by downregulating YAPLife Sci261118121202010.1016/j.lfs.2020.11812132693242SantinonGPocaterraADupontSControl of YAP/TAZ activity by metabolic and nutrient-sensing pathwaysTrends Cell Biol26289299201610.1016/j.tcb.2015.11.00426750334WangRYangSWangMZhouYLiXChenWLiuWHuangYWuJCaoJA sustainable approach to universal metabolic cancer diagnosisNat Sustain7602615202410.1038/s41893-024-01323-9KashiharaTMukaiROkaSIZhaiPNakadaYYangZMizushimaWNakaharaTWarrenJSAbdellatifMSadoshimaJYAP mediates compensatory cardiac hypertrophy through aerobic glycolysis in response to pressure overloadJ Clin Invest132e150595202210.1172/JCI15059535133975LiXWuZHeJJinYChuCCaoYGuFWangHHouCLiuXZouQOGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAPOncogene4048594871202110.1038/s41388-021-01901-734155345ZhangXQiaoYWuQChenYZouSLiuXZhuGZhaoYChenYYuYThe essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesisNat Commun815280201710.1038/ncomms1528028474680PeiCWangYDingYLiRShuWZengYYinXWanJDesigned concave octahedron heterostructures decode distinct metabolic patterns of epithelial ovarian tumorsAdv Mater352209083202310.1002/adma.202209083SunTChiJTRegulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implicationsGenes Dis8241249202110.1016/j.gendis.2020.05.00433997171WeiCFuQCell death mediated by nanotechnology via the cuproptosis pathway: A novel horizon for cancer therapyVIEW420230001202310.1002/VIW.20230001
Hippo signaling pathway is a key regulator of cellular and systemic metabolism, maintaining organ size and tissue homeostasis by controlling cell proliferation, survival and regeneration. When the Hippo signaling pathway is activated (in the ‘ON’ state), MST1/2 kinases phosphorylate LATS1/2, which in turn promotes the phosphorylation of YAP/TAZ. This leads to the retention of YAP/TAZ in the cytoplasm and/or their degradation via the proteasome pathway, thereby inhibiting their transcriptional co-activator activity. Conversely, when the Hippo signaling pathway is inactivated (in the ‘OFF’ state), dephosphorylated YAP/TAZ can freely translocate to the nucleus, where they bind to the TEAD family of transcription factors and activate the expression of a range of genes involved in cell growth, proliferation, and survival. MST, macrophage-stimulating; LATS1/2, large tumor suppressor kinase 1/2; YAP, Yes-associated protein; TAZ, transcriptional co-activator with PDZ-binding motif; TEAD, TEA domain; SAV1, Salvador family WW domain-containing protein 1; MOB1, MOB kinase activator 1; P, phosphorylated.
In bladder cancer, YAP1 activity is regulated by YAP1 gene expression, post-transcriptional mRNA modifications, and the activity of the Hippo signaling pathway. YAP1 protein modifications also affect its activity and function. 4-HNE regulates YAP1 activity through phosphorylation, accelerating its degradation, while MINDY enhances its stability through deubiquitination. Activated YAP1 will enter the nucleus and bind to TEAD to regulate downstream target genes. 4-HNE, 4-hydroxynonenal; YAP, Yes-associated protein; LATS1/2, large tumor suppressor kinase 1/2; DUB, deubiquitination; TEAD, TEA domain.
In bladder cancer cell lines, YAP1 and its downstream signaling pathways influence various biological behaviors of bladder cancer.
Signaling network
Major outcomes
Cell line used/bladder subtype
(Refs.)
YAP1/Mask2
Overexpression of YAP1 can promote the growth and migration of bladder cancer cells. The YAP1/Mask2 complex controls the growth and migration of bladder cancer cells by regulating the expression of target genes in the Hippo pathway.
5637
(28)
YAP1/MAPK
YAP1 overexpression activates proteins and their phosphorylated forms in the MAPK pathway, including ERK, p38 and JNK, thereby enhancing the cellular proliferative capacity and invasiveness of bladder cancer cells.
5637/UMUC-3/J82
(30)
YAP1/H19
YAP1 expression is significantly upregulated in bladder cancer and facilitates cancer cell proliferation and migration by increasing the expression of the long non-coding RNA H19.
5637/UMUC-3
(32)
YAP1/TGF-β/Smad
MiRNAs miR-497 and miR-195 inhibit the expression and interaction of YAP1 and Smad3, thereby diminishing the activity of the YAP1-Smad3 complex and consequently suppressing the progression of bladder cancer.
5637/T24
(36)
HIC1/YAP1
Overexpression of HIC1 reduces the binding of YAP1 to TEAD, inhibits the activity of the YAP1/TEAD pathway, and thereby suppresses the progression of bladder cancer.
J28/T24
(37)
YAP1/COX2/PGE2
YAP1 and the COX2/PGE2 signaling pathway synergistically activate SOX2, thereby promoting cancer stem cell properties and enhancing chemotherapy resistance.
BFTC905/BFTC909/5637/T24
(53)
In multiple bladder cancer cell lines, YAP1 is integrated into signaling networks, influencing the progression of bladder cancer. Specifically, YAP1 interacts with signaling pathways such as Mask2 and MAPK, and collaborates with H19 and HIC1. HIC1, hypermethylated in cancer 1; COX2, cyclooxygenase 2; YAP, Yes-associated protein; PGE2, prostaglandin E2.
Main mechanism and mode of action of YAP1 in the treatment of bladder cancer.
Treatment method
Mechanism of action
Functions
(Refs.)
Chemotherapy: Resistance
YAP1 contributes to chemoresistance and antioxidant response in bladder cancer cells by regulating the expression of Nrf2 and FOXM1 and modulating intracellular oxidative stress levels.
YAP1 maintains cellular antioxidant status by regulating the intracellular antioxidant system, specifically through the modulation of GSH synthesis and utilization.
(65)
YAP1 increases the chemoresistance of bladder urothelial carcinoma cells to drugs such as cisplatin by inhibiting apoptosis and promoting cell survival signaling pathways.
Activation of YAP1 decreases cellular sensitivity to DNA-damaging drugs and inhibits the apoptotic pathway by reducing the activation of apoptosis-related proteins caspase 3 and PARP induced by chemotherapy.
(71)
Immunotherapy
Knockdown of YAP1 reduces cell invasiveness and migratory ability, likely due to the involvement of YAP1-regulated genes such as CTGF and CYR61, which play crucial roles in extracellular matrix remodeling and cell migration.
YAP1 plays a critical role in the proliferation, colony formation, invasiveness and migratory ability of bladder cancer cells by regulating multiple molecules and signaling pathways involved in cell cycle progression, migration, invasion and gene expression.
(80)
Molecular Targeted Therapy:
Verteporfin inhibits bladder cancer cell growth and invasion by suppressing the expression of downstream genes in the Hippo signaling pathway activated by YAP1.
The function of YAP1 is inhibited, which in turn suppresses the expression of target genes in the Hippo signaling pathway, thereby inhibiting the growth and invasion of bladder cancer cells.
(85)
Knocking down YAP1 can inhibit chemoresistance in bladder cancer. YAP1 may also serve as a biomarker for bladder cancer immunotherapy. Additionally, the YAP1-targeting drug VP inhibits the proliferation and migration of bladder cancer cells. CRY61, cysteine-rich angiogenic inducer 61; YAP1, Yes-associated protein 1; Nrf2, nuclear factor erythroid 2-related factor 2; FOXM1, forkhead box M1; GSH, glutathione; CTGF, connective tissue growth factor.